IP Library Granted Patent US 10,226,419
Granted Patent B2
US 10,226,419 · App. 14/847,782 · Granted Mar 12, 2019

Methods for manufacturing implants

Inventors: James H. Arps (Chanhassen, MN); Matthew Petersen (Minneapolis, MN)
Assignee: PROMED PHARMA, LLC
A61K9/0036A61K31/567A61K31/57A61K47/32A61K47/34B29C51/12B29C47/0011B29C47/028B29K2067/046B29K2105/0035B29L2031/7148B29L2031/754
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,226,419
App. No.
14/847,782
Granted
Mar 12, 2019
Kind
B2
Abstract

Pharmacologically active implants, in particular subcutaneous implants, intrauterine devices, and intravaginal rings, are provided herein. Methods for forming an active ingredient-containing core are described. Methods for laminating an active ingredient-containing core to form a rate-controlling sheath are also described.

Claims (15)

1. A method of forming a rate-controlling release membrane over a pharmacologically active ring-shaped core, the method comprising:

positioning the ring-shaped core between two layers of film;

applying one or more of heat and pressure to the core and film layers such that each film layer mechanically combines with one or more of the ring-shaped core and the other film layer; and

trimming excess film to form a sheath having a substantially uniform thickness.

2. The method of claim 1 , wherein the ring-shaped core has a continuous shape.

3. The method of claim 1 , wherein the ring-shaped core comprises at least one polymer and at least one active ingredient.

4. The method of claim 3 , wherein the ring-shaped core further comprises one or more of an opacifier or a dye.

5. The method of claim 3 , wherein the one or more polymers comprise one or more of poly lactic-co-glycolic acid and ethylene vinyl acetate.

6. The method of claim 5 , wherein the ethylene vinyl acetate comprises about 10 wt. % to about 40 wt. % vinyl acetate.

7. The method of claim 3 , wherein the active ingredient comprises a contraceptive hormone.

8. The method of claim 3 , wherein the active ingredient comprises one or more of estradiol, ethinyl estradiol, etonogestrel, progesterone, ethisterone, norethisterone acetate, norethynodrel, levonorgestrel, or gestodene.

9. The method of claim 3 , wherein the film layers have a thickness of about 1 mil to about 25 mils.

10. The method of claim 1 , wherein the film layers comprise one or more of poly lactic-co-glycolic acid and ethylene vinyl acetate.

11. The method of claim 1 , wherein applying one or more of heat and pressure to the core and film layers comprises applying pressure between about 15 to about 20 tons of force.

12. The method of claim 1 , wherein heat is applied at a temperature that exceeds the melting point of one or more polymers by about 10%.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 8, 2015
From: ARPS, JAMES H; PETERSEN, MATTHEW
To: PROMED PHARMA, LLC
Reel/Frame 036756/0984 →
Continuity (2)
Provisional Application 62047344 · Sep 8, 2014
Related Publication 20160067178A1 · Mar 10, 2016
Cited By (2)
US 12,472,148 US 12,502,360